Collaborations and Translation of Science
Babraham scientists collaborate with research academic research groups and companies both within the UK and internationally. Where the knowledge generated from the Institute’s research has potential for application, our scientists work with clinicians or with companies to translate the research into action for social and economic benefit.
By its nature, the Institute’s research is not immediately close to application and timescales to reveal opportunities for translation can be lengthy, requiring years of focused and evolving research effort. For instance, licensing royalty income from Abgenix Inc. only came on stream in 2007 following a patent obtained in 1988 jointly with the MRC involving expression of humanized antibodies in mice. This technology has led to the company developing a therapeutic product to treat metastatic colorectal cancer (Vectibix TM –the first fully human anti-EGFR monoclonal antibody). Please visit the Babraham Institute website for more information.
